



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Baker et al.)	Group Art Unit Unknown
)	
Appl. No.	:	10/015,393)	
)	
Filed	:	December 11, 2001)	
)	
For	:	SECRETED AND)	
		TRANSMEMBRANE)	
		POLYPEPTIDES AND NUCLEIC)	
		ACIDS ENCODING THE SAME)	
)	
Examiner	:	Unknown)	

SECOND PRELIMINARY AMENDMENT

United States Patent and Trademark Office
 PO Box 2327
 Arlington, VA 22202

Dear Sir:


In response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures mailed on April 16, 2002, setting a two-months term, Applicants hereby request the entry of the substitute "Sequence Listing" submitted concurrently herewith into the specification, starting on a new page, immediately following the claims. The present substitute Sequence Listing serves to replace the Sequence Listing filed on December 11, 2001.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: June 5, 2002

By: 

Ginger R. Dreger
 Registration No. 33,055
 Attorney of Record
 620 Newport Center Drive
 Sixteenth Floor
 Newport Beach, CA 92660

#3

GNE.P2830P1C46

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Baker et al.)	Group Art Unit Unknown
)	
Appl. No.	:	10/015,393)	
)	
Filed	:	December 11, 2001)	
)	
For	:	SECRETED AND)	
		TRANSMEMBRANE)	
		POLYPEPTIDES AND NUCLEIC)	
		ACIDS ENCODING THE SAME)	
)	
Examiner	:	Unknown)	

SEQUENCE SUBMISSION STATEMENT

United States Patent and Trademark Office
PO Box 2327
Arlington, VA 22202

Dear Sir:

This is in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed April 16, 2002. I hereby state that the amendments, made in accordance with 37 C.F.R. § 1.825(a) and included in the Substitute Sequence Listing submitted herewith, are supported in the application, and that the Substitute Sequence Listing does not include new matter.


I further state that the information recorded in the currently submitted substitute copy of the computer-readable form of the Sequence Listing is identical to the paper form of the Sequence Listing submitted herewith as required in 37 C.F.R. § 1.825(b).


Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: June 5, 2002

By: 
Ginger R. Dreger
Registration No. 33,055
Attorney of Record
620 Newport Center Drive, 16th Floor
Newport Beach, CA 92660
(415) 954-4114



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/015,393	12/11/2001	Kevin P. Baker	P2830P1C46

CONFIRMATION NO. 9822

FORMALITIES LETTER



OC000000007876519

Ginger R. Dreger
Knobbe Martens Olson & Bear
Suite 1150
201 California Street
San Francisco, CA 94111

Date Mailed: 04/16/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE